Home

About Us

Site Map

Search for

Online Learning & Teaching

Webcasts

ESC Slide Resource

World Congress of Cardiology - ESC Congress 2006

ESC Congress 2005 Stockholm

ESC Congress 2004 Munich

ESC Congress 2003 Vienna

Management of CVD Risk in the Perimenopausal Woman 2006

EACPR Leuven Spring Meeting 2005

Heart Failure 2005

ESC Policy Conference on CVD in Women

Education in Heart

Educational Programme Resources

Scientific and Knowledge Search

Clinical Case Portal
Echocardiography

Heart Failure Scientific Reports

CME Calendar

Candesartan in heart failure (CHARM programme)

Presentation title: Candesartan in heart failure (CHARM programme)

Author(s): C.B. Granger (Durham NC, US)J.J.V. McMurray (Glasgow, GB)S.Yusuf (Hamilton, CA)K.Swedberg (Gothenburg, SE)M.A. Pfeffer (Boston, US)

Date: 31 August 2003

[Download complete file]

Click a thumbnail below to view an individual slide:
Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity	Conflicts of interest	Background (1)
Background (2)	Aims: CHARM Programme	CHARM Programme
Countries and national leaders	Recruitment in the three component CHARM-trials	Inclusion and exclusion criteria
Study designDose-titration and visit schedule	Statistical methods	Statistical methods (2)
Baseline characteristics (1)	Baseline characteristics (2)	Baseline characteristics (3)
CHARM Programme	CHARM-AlternativeBackground	CHARM-AlternativePatient disposition
Baseline characteristics	Baseline characteristics	CHARM-AlternativeBaseline characteristics (2)
CHARM-Alternative: Primary outcome CV death or CHF hospitalisation	CHARM-Alternative: Secondary outcomes	CHARM-Alternative: Investigator reported CHF hospitalisations
CHARM-Alternative: Permanent study drug discontinuations	CHARM-Alternative: Permanent study drug discontinuations	CHARM-AlternativeConclusions
CHARM Programme	CHARM-Added:Background	CHARM-AddedPatient disposition
Baseline characteristics	Baseline characteristics	CHARM-AddedBaseline ACE inhibitor
CHARM-Added: Primary outcomeCV death or CHF hospitalisation	CHARM-Added: Secondary outcomes	CHARM-Added:Prespecified subgroups, CV death or CHF hosp.
CHARM-Added: Investigator reported CHF hospitalisations	CHARM-Added: Permanent study drug discontinuations	CHARM-Added:Conclusions
CHARM Programme	CHARM-Preserved: Background	CHARM-PreservedPatient disposition
Baseline characteristics	Baseline signs, symptoms and radiographic findings	Baseline characteristics
CHARM-Preserved: Primary outcome CV death or CHF hospitalisation	CHARM-Preserved: Primary and secondary outcomes	CHARM-Preserved: Investigator reported outcomes
CHARM-Preserved: Investigator reported CHF hospitalisations	CHARM-Preserved: New diagnosis of diabetes mellitus	CHARM-Preserved: Permanent study drug discontinuations
CHARM-Preserved:Conclusions	CHARM-Preserved	CHARM Programme
CHARM-Overall:Patient disposition	CHARM-Overall: All-cause death	CHARM-Overall: CV death and non-CV death
CHARM-Overall:CV death or CHF hosp.	CHARM Programme Mortality and morbidity	CHARM-Overall:Secondary composite outcomes
CV death or hospitalisation for CHF	CV death or hospitalisation for CHF	CHARM - Low EF (Alternative and Added) All-cause death
CHARM - Low EF (Alternative and Added) Primary and secondary outcomes	CHARM-Overall: Investigator reported CHF hospitalisations	CHARM-Overall:New diagnosis of diabetes mellitus
CHARM-Overall:Permanent study drug discontinuations	CHARM-Overall: Conclusions	CHARM-Overall:Implications

Visit the beta version of the new ESC Web Site

There are no polls available right now.

Site Map | Contact Us | Terms & Conditions | Privacy